Trials / Completed
CompletedNCT02896868
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to investigate the safety and tolerability of the study drug known as LY3041658 in participants with certain types of skin diseases. The study will measure how the body absorbs, breaks down and gets rid of LY3041658. It will last about 127 days for each participant, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3041658 | Administered IV. |
| DRUG | Placebo | Administered IV. |
Timeline
- Start date
- 2016-11-08
- Primary completion
- 2019-03-19
- Completion
- 2019-03-19
- First posted
- 2016-09-12
- Last updated
- 2019-05-03
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02896868. Inclusion in this directory is not an endorsement.